Pancreatic Cancer Research

ResearcherJinan UniversityActive in the last 2 years

Yangyang Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0092-963X; OpenAlex author ID A5051501161. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 5

  1. Hypertension and tachycardia induced by irreversible electroporation in pancreatic cancer: An analysis based on clinical data. Co-author DOI 10.4240/wjgs.v17.i9.110577↗
  2. Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1193040↗
  3. Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1155/2022/3523769↗
  4. Irreversible electroporation for liver metastasis from pancreatic cancer: A case report. Co-author DOI 10.12998/wjcc.v8.i2.390↗
  5. Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer. Co-author DOI 10.12998/wjcc.v8.i22.5564↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lizhi Niu · 4 shared papers, 2020–2023 · strength 0.61
  2. Hongmei Li · 2 shared papers, 2023–2025 · strength 0.48
  3. Lizhi Niu · 1 shared paper, 2025 · strength 0.30
  4. Jibing Chen · 2 shared papers, 2020 · strength 0.28
  5. Shuying Li · 1 shared paper, 2023 · strength 0.18
  6. Mao Lin · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.